Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABA.sub.A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description. ##STR00001##

Compounds are provided according to Formulae (A-I), (B-I), (C-I), (D-I), (E-I), (F-I), (G-I), and (H-I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.

##STR00001## ##STR00002##

The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.

A process is described wherein, by employing 17-(3-hydroxypropyl)-6,7;15,16-dimethylene-5-androstane-3,5,17-triol (II) as starting product, in a single stage reaction there is obtained drospirenone, (I), a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic action, that is useful for preparing pharmaceutical compositions with contraceptive action. ##STR00001##

Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABA.sub.A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.

##STR00001##

Disclosed herein are a modified guayule resin product and related processes for preparing the modified guayule resin product. The modified guayule resin product comprises a mixture of argentatins having at least one functional group, wherein the at least one functional group is provided by an isocyanate-containing functionalizing compound. In a second embodiment, a process for preparing a modified guayule resin product is provided whereby a guayule resin component (comprising a mixture of argentatins) is mixed with an isocyanate-containing functionalizing compound to produce a modified guayule resin comprising functionalized argentatins having at least one functional group provided by the isocyanate-containing functionalizing compound.

A compound of formula (I-A), R.sup.1 in each occurrence is selected from H, optionally substituted C.sub.1-12 alkyl and optionally substituted C.sub.6-20 aryl; R.sup.2 in each occurrence is selected from optionally substituted C.sub.1-12 alkyl and optionally substituted C.sub.6-20 aryl; p is 1 and q is 5 or pis 2 and q is 4; p+q=6; Y is an anion; and n is 1 or 2. The compounds of formula (I-A) may be used to catalyse reactions including arylation and alkylation at the carbon atom of a CH group in which the C atom is sp.sup.2-hybridised.

##STR00001##

The invention describes novel steroidal compounds, compositions containing the same, and methods of using the same as SREBP inhibitors, as LXR agonists, or as dual modulators of SREBP and LXR, to treat SREBP and/or LXR mediated diseases.

A fully-continuous synthesis method of cyproterone acetate is provided. 4-androstene-3,17-dione is adopted as a starting material. The present disclosure adopts a fully continuous device composed of micromixers, microreactors, online gravity separation units, online solvent switching units, online solvent concentration units and solvent recovery systems connected according to a cyproterone acetate synthesis route. Cyproterone acetate product is synthesized through one enzymatic catalytic reaction, nine chemical reactions and continuous operations. This can realize recovery of dichloromethane, dichloroethane and ethanol, and significantly reduce emission of three wastes. The obtained crude cyproterone acetate is subjected to decolorization, recrystallization, filtration and drying to obtain pure cyproterone acetate with a purity greater than 99%.